ArticleAntibody therapeutics2021

Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action.

Wenyan Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.